, can be conceived as an anchoring point for heterochimeric molecules with novel properties an intermediary multimerizing system through which two or more molecular species can be associated to form heteromulsuch as enzymatic activities. The Rh(D) antigen is responsible for anti-Rh(D) alloimmunization by transfusion and, timers. This second approach, susceptible to more general applications is the one we have chosen for the present work.
M
C4bp fragment. These molecules are homomultimers, which maintain their capacity to recognize antigen but have a higher ULTIVALENT EXPRESSION of antibody combining sites allows the creation of complexes that are multivalent and can be multispecific and are, thus, susceptivalence number. We have elected to use an anti-Rh(D) human single-chain ble to a spectrum of therapeutic and diagnostic applications.
Multimerization of chimera molecules can be conceived Fv as a model system for multimerization. Rh antigen D is borne by a transmembrane unglycosylated protein. Rh according to different principles. Two possible orientations are direct coupling of the entities concerned or the use of antigens, such as Rh(D), can be conceived as an anchoring point for heterochimeric molecules with novel properties an intermediary multimerizing system through which two or more molecular species can be associated to form heteromulsuch as enzymatic activities. The Rh(D) antigen is responsible for anti-Rh(D) alloimmunization by transfusion and, timers. This second approach, susceptible to more general applications is the one we have chosen for the present work.
through materno-fetal immunization, is the most common cause of hemolytic disease of the newborn. Postpartum preIn a therapeutic perspective, to be nonimmunogenic and as inert in vivo as possible, the fragment conferring multimerizvention of alloimmunization is at the present time affected by injection of human polyclonal anti-Rh(D). In the search ing potential should derive from a physiological constituent of human plasma and should not activate complement.
for a future replacement a multimeric structure of a monoclonal derived anti-Rh(D) scFv is a first step in the construcThe C4 binding protein (C4bp) molecule, a normal plasma protein, [1] [2] [3] [4] [5] is a spider-like structure (570 kD) made of 7 ation of a heteromultimeric molecule that can serve to target Rh(D)-positive red blood cells (RBCs) to selected antibodychains and 1 b-chain. Binding sites for C4bp molecules are located on a-chains, whereas the protein-S binding site is dependent cell-mediated cytotoxicity effector cells. located on the b-chain. A minor form made of only 7 a-
MATERIALS AND METHODS
chains is also present at a lower concentration in normal human plasma. A third 5a/1b-chain molecule has also been Cloning of Anti-Rh(D) pable of spontaneous multimerization through the associated amplification. The single-chain Fv was constructed according to the method described by Marks et al. 7 Amplification of VH and VL coding fragments was effected with the specific V gene family primers.
Cloning of the scFv Restriction enzymes and alkaline phosphatase used for cloning were purchased from Boehringer Mannheim (Meylan, France). The T4 DNA ligation kit used was from Ozyme (Montigny-Le-Bretonneux, France). The scFv construct was excised from the pHEN-1 vector by digestion at the HindIII and Not I sites, thus including the bacterial leader peptide pelB.
11 The amplified C4bp fragment was digested by Not I and Xho I. These two DNA fragments were linked to a dephosphorylated pKC3 vector 12 digested by HindIII and Xho I (Fig1) . Escherichia coli DH5 a host strain was transformed using the pKC3 scFv anti-Rh(D) C4bp construct (mRh1).
Transfection of Chinese Hamster Ovary (CHO) Eukaryotic Cell Line and Amplification of the Transfected mRh1 Genes
Dihydrofolate reductase (dhFr) negative CHO cells (ATCC CRL-9096; American Type Culture Collection, Rockville, MD) were used for transfection.
Transfection was performed using a calcium phosphate transfection kit (5 Prime-3 Prime Inc, TEBU, Le Perray En Yvelines, France). Plasmid pKC3 scFv anti-Rh(D) C4bp or pKC3 scFv antiRh(D) C4bp MYC Tag (Fig 1) was cotransfected with the dhFr selective plasmid ST4.
13 CHO transformed with the appropriate vectors were selected according to their ability to grow in nucleosidefree medium. The screening of positive clones was performed by direct hemagglutination. Subsequent selective cycling in the presence of increasing concentrations (0.02 to 80 mmol/L) of amethopterin (Methotrexate; Sigma, St Louis, MO), a potent inhibitor of dhFr function, resulted in an amplification of the integrated DNA and an increased expression of the multimeric scFv. then assessed in Sepharose columns after a 1,000g centrifugation of 10 minutes at room temperature.
Direct Hemagglutination

Immunoprecipitation
GCCGCAGAACAAAAACTCATCTCAGAAGAGGATCTG-AATGAGACCCCCGAAGGCTGTGA-3; 5 primer without MYC Anti-MYC Tag monoclonal antibody (MoAb) 14 from MYC 1-Tag, 5-AGTGCGGCCGCAGAGACCCCCGAAGGCTGTGA-3; 9E10.2 (ATCC CRL-1729) cell line was purified using the octanoic 3 primer, 5-CTCGCGGCCGCCTCGAGTTATAGTTCTTTAacid, contra precipitation method 15 and biotinylated using a hydroxy-TCCAAAGTGG-3.
succinimide LC biotin linker (Pierce; Interchim, Montluçon, France) Underlined sequences represent restriction endonuclease sites.
according to the manufacturer's instructions. The 5 and 3 primers contain Not I and Xho I sites, respectively.
A total of 3 1 10 6 cells in a 75-cm 2 flask were labeled during 24 The sequence depicted in bold characters codes for the MYC Tag hours at 37ЊC using 170 mCi/mL 35 S methionine-cysteine (Amerpeptide.
10 Two different sequences were amplified. The first sesham, Les Ulis, France) in 7 mL of methionine and cysteine-free quence contained a stop codon and a restriction site for Xho I at its RPMI 1640 medium (ICN, Orsay, France) supplemented with 10% 3 end as well as a restriction site for Not I at its 5 end. The second heat-inactivated fetal calf serum and 2 mmol/L glutamine. Magnetic sequence also contained these flanking sequences as well as a coding beads coated with sheep antimouse IgG (Dynabeads; Dynal, Comsequence for the MYC Tag peptide at its 5 end, downstream to the piegne, France) were incubated with radiolabeled supernatant. After Not I site. This peptide allowed detection and characterization of washing, immunoprecipitated proteins were analyzed in sodium dothe recombinant protein (Fig 1) .
decyl sulphate-polyacrylamide gel (SDS-PAGE) under reducing and nonreducing conditions.
16
PCR Amplification Immunofluorescence Assays: Assessment of the Fixation of
Genomic DNA was used as a template for PCR amplification.
mRh1 on RBCs
The reaction mixture was subjected to 30 cycles of amplification using a Gene Amp PCR System 9600 (Perkin-Elmer, Foster City, Twenty microliters of a 2.5% suspension of papain-treated Rh(D) positive RBCs was incubated for 45 minutes at 37ЊC with 50 mL of CA). Cycles were of 1 minute at 94ЊC, 1 minute at 56ЊC, and 2 minutes at 72ЊC. DNA was then digested with Not I and Xho I. For personal use only. on August 31, 2017. by guest www.bloodjournal.org From supplemented with 1% bovine serum albumin, then incubated with 2 mg of biotinylated anti-MYC Tag MoAb. RBCs were then washed twice and stained with a biotin-avidin-enhancing system, as previously described.
17 Stained RBCs were fixed in 0.37% formaldehyde diluted in washing buffer and analyzed on a FACStar Plus (Becton Dickinson, Mountain View, CA). Papain-treated Rh(D)-negative RBCs were used as a negative control. A competition assay using the anti-Rh(D) DF5 human MoAb, from which the scFv originated, was performed to assess the specificity of binding of mRh1 to RBCs. For longitudinal testing experiments, fluorescent calibration beads (Becton Dickinson) and mouse IgG-coated beads (Qifikit; Biocytex, Marseille, France) were used to standardize day-to-day settings of the apparatus. , was then added, and suggested that the molecular formula of the multivalent molthe mixture was incubated for 30 minutes at 37ЊC. Human C3b ecule mRh1 was an octamer, like the natural major C4bp deposits were revealed by fluorescein-labeled goat antiserum against component (Fig 3) . quantification, possibly because of the position of the tag at the center of the spider-like structure. With the same vector,
Complement Fixation Tests
RESULTS
other multimerized molecules (CD4 or CD16) regularly reach a stable secretion level of 1 to 3 mg/mL, which can Multivalent anti-Rh(D) recombinant proteins were obtained with C4bp and C4bp MYC Tag multimerizing fragbe assumed as the secretion range of mRh1, whereas, with a more powerful vector, engineered CD46 reaches a 10 to ments. They were soluble and stable in culture supernatant.
These mRh1 directly agglutinated papain-treated Rh(D)-20 mg/mL secretion level (manuscript in preparation). Flow cytometry analysis showed that the binding of mRh1 positive RBCs, as did anti-Rh(D) MoAb DF5 (Fig 2) , unlike monomeric anti-Rh(D) scFv (data not shown), and could was strikingly better on papain-treated RBCs and during a warm incubation. also, less intensively, agglutinate native RBCs, which the parent DF5 MoAb did not. These recombinant multimers Flow cytometry competition experiments between mRh1 and human anti-Rh(D) DF5 MoAb, from which originated proved stable: Supernatants produced in the course of this work are functional by direct agglutination after 2 years the binding site of mRh1, showed a dose-dependent inhibition validating the specificity of mRh1 binding on RBCs. In at 4ЊC, and testing of mRh1 supernatants every week for accelerated aging during 1 month at 37ЊC showed no significomplement lysis experiments, no complement fixation was found on mRh1 coated RBCs whereas a significant lysis was cant decrease in staining intensity in flow cytometry binding assays.
observed antibody enhancing system was used as a positive control components of plasma and may prove immunogenic. Other approaches to dimerization of scFv have been proposed, 32 of both mRh1 binding and complement potency (Fig 4) . Taken together, these data showed the secretion by mRh1-such as diabodies. 33 Nevertheless dimeric structures may not be optimal for given applications. transfected CHO cells of a unique soluble multimeric molecule with multivalent antibody properties, devoid of any Multimeric constructions, such as those described by Ito et al, 23 based on fusion to protein A, can generate complexes complement fixation activity.
of Fv-protein A and IgG with variable stoichiometry or by
DISCUSSION
Dübel et al, 34 in which scFv are fused to a core-streptavidin structure allowed the creation of tetrameric antibodies with The use of molecules of human origin for therapy began additional coupling possibilities because of the presence of with the use of polyclonal whole antisera. MoAb allowed biotin binding sites and cysteines. The use of a heteroantiproduction of better defined molecules, which led to reprogenic fragment, protein A, or streptavidin carries the risk of ducible and well-controlled products. However, their use an immune response which could seriously limit potential remained mostly limited to situations in which the destructherapeutic applications. tion of a target is needed because of the properties of the Fc The C-terminal C4bp multimerizing system fulfills the fragment of Igs. Artificial structures such as single chain requirement of a multi-purpose multimerizing system for antibodies 7, 9, [19] [20] [21] generally have a short half-life, have a low future in vivo use. avidity because of their single valence, and are, in most This study established that the C terminal part of the acircumstances, unable to trigger biological functions alone. chain of C4bp is sufficient to induce polymerization during The association of different structures in a given recombiprotein synthesis, and, although the expression vector codes nant molecule has been hampered by problems because of only for monomers, multimers are assembled in the cell conformation and accessibility. Different approaches have without necessity for secondary modifications resulting in been proposed to obtain bivalent or multivalent molecules.
the secretion of a unique, covalently linked soluble molecule. Chemical linkage of proteins to polyethylene-glycol or dexThis research model can be further optimized to meet the tran is cumbersome, requiring large amounts of purified maneeds of high-level production. Clearly, production system, terial.
22 Disulfide linking of Fcg or use of Fcm fragments to vectors, leader sequence and junction area at the 5 end of create multivalent Ig molecules [23] [24] [25] [26] [27] [28] [29] has been proposed to the C4bp multimerizing system have to be optimized for maintain and amplify Fc-mediated functions. However the that purpose. The multimerizing structure originates from a enhancement of Fc-associated reactivity, such as antigennormal component of human plasma avoiding immunization. independent complement activation, can be undesirable in It does not impair the solubility of multimeric molecules a therapeutic context. The molecules synthesized in these and lacks any biological function. Although only electron systems have been heterogeneous, varying from monomers microscopy images will resolve the question with certainty, to hexamers and higher order structures. Dimerization of it seems reasonable to believe that the three multimeric forms smaller F(ab)2 or Fv structures has been effected through observed before cloning were the counterpart of the physiothe use of amphiphatic helices, either leucine zippers or bunlogical forms of C4bp, because their relative proportions dle-helix constructs.
30,31 The former do not satisfactorily rewere also in accordance with the physiological pattern: There act to the introduction of a covalent link and, thus, are potentially unstable; furthermore, these molecules are not natural was a major representation of structures with eight valences, AID Multibodies may also be developed from this model of multi-scFv, associating different antibody binding sites against various epitopes of a given antigen, to maintain the avidity of polyclonal antisera by mimicking the cooperative effect of different antibodies in polyclonal antisera.
Future developments of this system towards heterofunctional multimeric molecules will include the use of C terminal parts of both a-and b-C4bp chains or the use of modified a-chains to control the ratio of two components in heterochimeric molecules and to modulate the polymerization process. These heterofunctional multimeric molecules will either retain the lack of complement activation properties of this system, for example for enzyme replacement therapy or imaging, or will incorporate complement activating or cell attracting molecules to promote the clearance of targeted cells. In the future, new recombinant molecules for clearing Rh(D)-positive RBCs and preventing Rh alloimmunization may be designed from this system. 
